

AMENDMENT

Serial Number: 09/313,048

Filing Date: May 17, 1999

Title: THIAZOLOPYRIMIDINES USEFUL AS TNF $\alpha$  INHIBITORS

Page 2

Dkt: 103.009US1

- Q2
3. (Amended) The compound of claim 1 or 2 wherein A is [CO<sub>2</sub>R] CO<sub>2</sub>R<sup>3</sup>.
4. (Amended) The compound of claim 3 wherein R<sup>3</sup> is H or (C<sub>1</sub>-C<sub>6</sub>)alkyl, optionally substituted with OH, C<sub>6</sub>-C<sub>10</sub> heteroaryl or [OZ, wherein Z is] an ester of an amino acid.
5. (Amended) The compound of claim 4 wherein [Z] the ester of the amino acid is an L-valine residue or L-glycine residue.
6. (Amended) The compound of claim 4 wherein [Z is] R<sup>3</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkyl substituted with 4-pyridyl.
7. (Amended) The compound of claim 1 or 2 wherein [R<sup>1</sup>] -Z-A is ethoxycarbonylpropyl.

- Q3
11. (Amended) A therapeutical method for treating a pathological [condition] inflammatory response associated with [TNF $\alpha$  release] overproduction of proinflammatory cytokines comprising administering to a mammal in need of such treatment an amount of a compound of claim 1 effective to inhibit said overproduction so as to treat said pathological [condition] inflammatory response.

In claims 13-14, line 1, delete "12" and insert --11--.

Please add the following claims:

- Q4
15. (New) The method of claim 11 wherein the proinflammatory cytokines comprise TNF $\alpha$ .
16. (New) The method of claim 11 wherein the proinflammatory cytokines comprise IL-1.

IN THE SPECIFICATION

At page 3, line 5, delete "NNO(OH)" and insert --N(NO)(OH)--.

At page 3, line 6, after "SO<sub>2</sub>R<sup>3</sup>", insert --,--.

At page 3, line 8, delete "OZ wherein Z" and insert --OY wherein Y--.

28 A